CVS vs HUM: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CVS is the larger of the two ($110.20B market cap): the incumbent the market prices for continued execution (9.97x forward earnings, beta 0.58). HUM is the smaller challenger ($51.70B), actually pricier on forward earnings (24.79x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CVS vs HUM: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCVSHUMWhat it tells you
Market cap$110.20B$51.70BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E9.9724.79Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E10.0042.00Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.580.64Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range40% of range91% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.372.75How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: CVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CVS and HUM affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and HUM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and HUM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does CVS Health (CVS) do?

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

Full CVS guide

What does Humana (HUM) do?

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covered roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

Full HUM guide

CVS vs HUM: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
  • HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For HUM, the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025.

CVS or HUM: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; HUM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and HUM guides.

CVS vs HUM: the full fundamentals

CVS. CVS trades near 11x forward earnings and about 0.3x sales, a low multiple versus the broad market that reflects lingering caution after the 2023 to 2024 Aetna downturn and continuing PBM and legal risk rather than current results, which have beaten estimates four quarters running. Q3 2026 results are scheduled for November 4, 2026, with consensus adjusted EPS near $1.65 on ~$105 billion of revenue. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

HUM. At about $417, Humana trades near 39x trailing earnings, a figure inflated by depressed recent profits, and about 24x analysts' 2027 estimate, which assumes earnings nearly double next year as the margin recovery and star-ratings bonuses arrive. The stock trades at only about 0.34x sales, typical of a thin-margin insurer. Q3 2026 results are scheduled for November 6, with consensus calling for a seasonal loss of about $1.00 per share on revenue near $40.9 billion.

Headline figures (approximate, October 2026): CVS shows revenue (ttm) ~$413 billion (Q2 2026 ~$106B, up ~7% YoY), adjusted eps Q2 2026 $2.58 vs $1.85 estimate; 2026 consensus ~$8.04, 2027 ~$8.54, net income (ttm) ~$4.9 billion (net margin ~1.2%), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier; HUM shows revenue (ttm) ~$146 billion, revenue growth (q2 2026, yoy) ~26%, operating / net margin (ttm) ~3.5% / ~0.9%, adjusted eps (2026 / 2027 consensus) ~$9.16 / ~$17.09.

The bottom line: CVS vs HUM

CVS and HUM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and HUM exposure against your real portfolio. It is not an investment adviser.

Wondering how CVS or HUM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about CVS Health

Ask Walnut's AI anything about CVS and see how it fits what you own.

FAQ

What is the difference between CVS and HUM?

+

CVS Health runs three reporting segments. Humana Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CVS or HUM the better stock?

+

Neither is universally better. CVS is the larger incumbent; HUM is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CVS or HUM?

+

On forward P/E (as of November 2026), CVS trades at 9.97x and HUM at 24.79x, so CVS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CVS and HUM?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CVS vs HUM?

+

CVS: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. Legal costs continue: in October 2026 CVS agreed to a $315 million settlement of federal claims over opioid dispensing, with new controlled-substance oversight measures. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries about $76 billion of debt, much of it from the Aetna deal, which limits flexibility if the turnaround stalls. HUM: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Margins remain thin, with a trailing operating margin near 3.5% and net margin under 1%. Earnings are also seasonal: consensus calls for an adjusted loss of about $1.00 per share in Q3 2026 and about $7.86 in Q4, as Medicare Advantage costs build through the year. Star ratings are a second lever; the 2027 rebound helps, but ratings are recalculated every year and a slip would reduce CMS quality-bonus payments. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing, such as the 2027 PPO exits, can pressure profitability or cause member attrition if benefits are trimmed too far, and after a roughly 58% rally in 2026 more of the recovery is already priced in.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CVS or HUM; figures are approximate and dated (as of November 2026). Verify current data before investing.